Biomarkers for Prostate and Bladder Cancer
- Abbreviated Name
- Prostate & Bladder Cancer Biomarkers
- Lead Investigator
- Liu, Alvin Y. — University of Washington
- Coordinating Investigator
- Liu, Alvin Y. — University of Washington
- Involved Investigators
Abstact
CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.
Aims
Sort cancer cells from tumor specimens Determine gene expression (transcriptome) by Affymetrix DNA arrays Dataset analysis to identify cancer up-regulated genes encoding secreted or extracellular proteins Proteomic analysis (mass spectrometry, Western blotting) to validate increased cancer expression
Analytic Method
Genomics and proteomics. DNA microarray analysis of sorted cell types to identify cancer-specific genes encoding secreted/extracellular proteins. Mass spectrometry-based proteomics to measure protin levels in case vs. control urine samples.
Comments
Data analysis was done to evaluate data quality of Affymetrix arrays (mRNA expression correlation to protein expression by immunohistochemistry), to compare other publicly available prostate cancer datasets.
Biomarkers
Data Collections
- Protocol ID
- 114
- Protocol Type
- Single
- Field of Research
- Genomics
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of prostate